China NT Pharma Group Company Ltd
HKEX:1011
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
C
|
China NT Pharma Group Company Ltd
HKEX:1011
|
CN |
|
H
|
HiteJinro Holdings Co Ltd
KRX:000140
|
KR |
|
Mahamaya Steel Industries Ltd
NSE:MAHASTEEL
|
IN |
|
Medica Sur SAB de CV
BMV:MEDICAB
|
MX |
|
Zeria Pharmaceutical Co Ltd
TSE:4559
|
JP |
|
S
|
Shell PLC
NYSE:SHEL
|
UK |
|
O
|
Omesti Bhd
KLSE:OMESTI
|
MY |
|
D
|
Dida Inc
HKEX:2559
|
CN |
|
Standex International Corp
NYSE:SXI
|
US |
|
Hindustan Copper Ltd
NSE:HINDCOPPER
|
IN |
|
Lundin Mining Corp
TSX:LUN
|
CA |
|
Jyothy Labs Ltd
BSE:532926
|
IN |
|
Constellium SE
NYSE:CSTM
|
FR |
|
Niigata Kotsu Co Ltd
TSE:9017
|
JP |
China NT Pharma Group Company Ltd
China NT Pharma Group Co., Ltd. is a pharmaceutical company, which engages in the distribution, promotion, manufacturing as well as research and development of pharmaceuticals and vaccines. The company is headquartered in Suzhou, Jiangsu. The company went IPO on 2011-04-20. The firm mainly conducts its businesses through two segments. The Proprietary Product Production and Sales segment is engaged in the production and sales of NT branded products and generic drugs through its subsidiaries. The Miacalcic segment is engaged in the sales and marketing of miacalcic injectable and nasal spray branded products for treatment of bone pain caused by osteolysis and lower bone mass, as well as sub-licensing of intellectual property rights and distribution rights.
China NT Pharma Group Co., Ltd. is a pharmaceutical company, which engages in the distribution, promotion, manufacturing as well as research and development of pharmaceuticals and vaccines. The company is headquartered in Suzhou, Jiangsu. The company went IPO on 2011-04-20. The firm mainly conducts its businesses through two segments. The Proprietary Product Production and Sales segment is engaged in the production and sales of NT branded products and generic drugs through its subsidiaries. The Miacalcic segment is engaged in the sales and marketing of miacalcic injectable and nasal spray branded products for treatment of bone pain caused by osteolysis and lower bone mass, as well as sub-licensing of intellectual property rights and distribution rights.
